Mouse Models of Retinoblastoma in the MICRON Literature

About the MICRON Research Literature

These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.

All publication counts and figures reflect the complete indexed research collection.

Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.

Understanding Retinoblastoma

Retinoblastoma is a cancer of the developing retina, arising in early childhood and usually driven by loss of both copies of RB1.

It occurs in a heritable form, in which a damaged copy is carried in the germline and disease is often bilateral and multifocal, and a non-heritable form that is typically unilateral and unifocal.

Retinoblastoma in Experimental Research

Mouse work on retinoblastoma includes two quite different preparations that answer different questions.

In an orthotopic xenograft, human retinoblastoma cells are implanted into the eye of an immunodeficient host: that places human tumor cells in an ocular environment and supports testing of drugs against them, at the cost of a host without an intact immune system and without the germline genetics.

In a genetically engineered mouse such as the LHBETATAG line, a tumor arises in the animal's own retina and can be followed as it develops, though the initiating lesion is not the human RB1 one: losing Rb1 alone does not give a mouse retinoblastoma, and mouse genetic models reach a retinal tumor either by inactivating a second retinoblastoma-family gene alongside it or through a different driver such as the SV40 large T antigen.

Reading a result here means knowing which preparation produced it.

Mouse Models of Retinoblastoma

The mouse carries most of this work.

Transgenic and knockout lines allow a pathway to be removed or overexpressed, and cost, availability, short generation time and a large body of background data reinforce the choice.

A genetic manipulation constrains rather than isolates a mechanism: developmental compensation and pleiotropy remain possible.

Published MICRON Research: Retinoblastoma in Mice

This page lists 10 papers from the MICRON literature, published 2015 to 2025, that study retinoblastoma in mice.

Of these publications:

• 10 studies used mice as the primary retinoblastoma disease model.

Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published retinoblastoma research.

Which imaging and experimental techniques are used in these studies?

Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.

Capabilities and Limitations of Imaging Techniques

A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.

Optical Coherence Tomography

Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.

As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).

Intravitreal Injection / Delivery

Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.

Fundus Fluorescein Angiography

Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.

This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.

Laser Photocoagulation Models

A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease.

Ocular Implants / Sustained Release

A sustained-release system holds a compound in or on the eye and lets it out gradually, so exposure is maintained from one placement rather than from a series of doses. The class spans polymer and non-polymer solid depots, injectable and particulate carriers, and reservoir devices; the release period belongs to the platform and not to the route, and runs from days to years. What the approach is for is to separate the dosing interval from the procedure interval, holding exposure at the target for as long as the question runs, whether that is the few weeks of a short-lived model or the span of a lifelong disease, without an intervention for each dose. What it gives up is control after placement. The release profile has to be measured rather than assumed, altering or ending delivery may require a further procedure, biodegradable systems behave differently from removable ones, and the carrier sits in contact with ocular tissue, so how the eye tolerates it is part of the result and not a precondition of it.

Which MICRON systems and add-ons appear?

Which strains and genetic lines are used?

What other conditions are recorded on the same papers?

Which MICRON configurations appear in this work?

Configurations recorded in these papers, and the techniques recorded alongside them.

The papers

Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.